2. Apoptosis Metabolic Enzyme/Protease
  3. Apoptosis Mitochondrial Metabolism
  4. Anticancer agent 320

Anticancer agent 320 is a potent broad-spectrum anticancer agent, with low toxicity toward noncancerous cells. Anticancer agent 320 induces cell cycle arrest, DNA double-strand breaks, and early apoptosis. Anticancer agent 320 disrupts mitochondrial function in cancer cells. Anticancer agent 320 inhibits proliferation of lung, colon, and breast cancer cells. Anticancer agent 320 can be used for the research of lung carcinoma, colon carcinoma, breast carcinoma.

For research use only. We do not sell to patients.

Anticancer agent 320

Anticancer agent 320 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Anticancer agent 320 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Anticancer agent 320 is a potent broad-spectrum anticancer agent, with low toxicity toward noncancerous cells. Anticancer agent 320 induces cell cycle arrest, DNA double-strand breaks, and early apoptosis. Anticancer agent 320 disrupts mitochondrial function in cancer cells. Anticancer agent 320 inhibits proliferation of lung, colon, and breast cancer cells. Anticancer agent 320 can be used for the research of lung carcinoma, colon carcinoma, breast carcinoma[1].

In Vitro

Anticancer agent 320 (compound 6g) (3.125-50 μM) inhibits the viability of MCF7, A549, and HCT116 cancer cells with IC50 values of 0.89, 1.02 and 1.29 μM, respectively, while showing minimal toxicity to MRC-5 cells (≥100 μM)[1].
Anticancer agent 320 (0.89-1.29 μM; 72 h) induces G1 phase arrest in HCT116 and A549 cells, and induces G2 phase accumulation in MCF7 cells[1].
Anticancer agent 320 (0.89-1.29 μM; 72 h) induces DNA double-strand breaks in A549 and HCT116 cells, but does not significantly increase DNA damage in MCF7 cells[1].
Anticancer agent 320 (0.89-1.29 μM; 72 h) potently induces early apoptosis in A549 cells, and modestly induces early apoptosis in HCT116 and MCF7 cells[1].
Anticancer agent 320 (0.89-1.29 μM; 72 h) inhibits 3D spheroid growth in A549 cells and inhibits initial spheroid formation in MCF7 cells[1].
Anticancer agent 320 (0.89-1.29 μM; 72 h) inhibits long-term colony formation in A549, HCT116, and MCF7 cells, with the greatest effect observed in HCT116 cells[1].
Anticancer agent 320 exhibits favourable binding interactions with key cancer-related proteins, including the highest affinity for MAPK8 with a docking score of -7.872 kcal/mol and MM-GBSA binding free energy of -55.11 kcal/mol[1].
Anticancer agent 320 reduces membrane potential in A549, HCT116, and MCF7 cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anticancer agent 320 Related Antibodies

Cell Cycle Analysis[1]

Cell Line: A549, HCT116, MCF7
Concentration: 0.89 (MCF7), 1.02 (A549) and 1.29 μM (HCT116)
Incubation Time: 72 h
Result: Increased G1 phase occupancy to 43.1% and reduced S phase to 31.1% in HCT116 cells, indicating G1 phase arrest.
Increased G1 phase occupancy to 62.6% and reduced S phase to 18.8% in A549 cells, indicating G1 phase arrest.
Increased G1 phase to 69.6% and significantly increased G2 phase to 30.3% in MCF7 cells, indicating a unique G2 phase accumulation profile distinct from the G1 arrest seen in other cell lines.

Apoptosis Analysis[1]

Cell Line: A549, HCT116, MCF7
Concentration: 0.89 (MCF7), 1.02 (A549) and 1.29 μM (HCT116)
Incubation Time: 72 h
Result: Induced early apoptosis in 77.83% of A549 cells, leaving only 10.07% of cells viable.
Induced early apoptosis in 14.98% of HCT116 cells, with 70.58% of cells remaining viable.
Induced early apoptosis in 23.1% of MCF7 cells.
Molecular Weight

369.39

Formula

C20H20FN3O3
SMILES

CCC(N1C(C(C(NCC2=NC=CC=C2)=O)=C(C3=CC(F)=CC=C31)O)=O)C
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Anticancer agent 320 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Anticancer agent 320Anticancer agent320Anticancer agent-320ApoptosisMitochondrial Metabolismcolon carcinomaSRCHCT116ESR1MAPK8HSP90AA1MRC-5lung carcinomaMCF7A549Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Anticancer agent 320
Cat. No.:
HY-183319
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.